… bacteraemia in hospitalized patients, even … mortality of 20% among the non-ESBL patients
in the studies we included. If we take this proportion as the expected mortality among patients …

… , mortality and hospital costs. Any delay in the initiation of adequate antibiotic therapy is
potentially lethal for patients … on risk factors for these infections and factors related to mortality. …

Bloodstream infections (BSI) caused by extended-spectrum β-lactamase (ESBL)-producing
organisms markedly increase the rates of treatment failure and death. We conducted a …

… a comparison group assessing all-cause mortality, attributable mortality and overall LOS
and intensive care unit stay (ICU) LOS in hospitalised patients with ESBL infections. Studies …

… This study was conducted to evaluate risk factors for mortality and treatment outcome of
bloodstream infections due to extended-spectrum beta-lactamase (ESBL)-producing Escherichia …

We performed a retrospective matched-cohort study to determine the risk factors for mortality
among patients with Escherichia coli infections. From January 1996 to December 2003, 100 …

… Despite the rapid emergence of ESBL-P organisms worldwide, their clinical significance
and impact on patient mortality have yet to be determined. We undertook an 8-month …

… In conclusion, we found the mortality rate among patients with ESBL-EK infections to be
high, approaching 20% in this cohort study. Inadequate initial antimicrobial therapy was an …

… mortality rate of our study sample was low, patients with liver disease or intra-abdominal
infection had significantly higher mortality, … Most of our patients with intra-abdominal infections …

… Infections due to multidrug resistant (MDR) gram negative organisms particularly those
producing extended spectrum β lactamases (ESBLs) are of major concern worldwide [1], [2], [3], [4…